Foster, Rachel H.; McClellan, Karen J. - In: PharmacoEconomics 16 (1999) 6, pp. 743-755
being diarrhoea. _ In a German cost-effectiveness model, a treatment programme including acamprosate was the dominant … strategy, producing a lifetime cost saving of 2602 Deutschmarks (1992 to 1995 values) per additional abstinent patient compared … acamprosate in alcohol-dependent patients. _ The main factors in the cost savings with acamprosate in these models were reduced …